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Abstract: Thymoma is a rare tumor, although it is the most common
primary neoplasm of the anterior mediastinum. In the majority of
thymoma patients, imaging is requested for investigation of symp-
toms related to their tumor, although an increasing number of
asymptomatic patients are discovered incidentally due to the in-
creased utilization of computed tomography for screening or for
imaging of other unrelated diseases. This review will focus on the
goals of imaging thymoma, the imaging features of thymoma, as
well as the advantages and limitations of each imaging modality in
establishing the diagnosis, staging, and prognosis of thymoma.
Key Words: Thymomas, Computed tomography (CT), Chest radi-
ography, Magnetic resonance imaging, Nuclear medicine.
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Thymomas are the most common primary neoplasm of theanterior mediastinum but account for less than 1% of all
adult malignancies.1 The majority arise in the upper anterior
mediastinum in proximity to the pulmonary artery and/or
ascending aorta, corresponding to the position of the normal
thymus. Rarely, however, they can be found in unusual
locations such as the posterior mediastinum or lower neck.2,3
Thymomas are usually slow-growing tumors manifesting
with local extension, which tend to spread along the serosal
surfaces, i.e., along the pleura and pericardium, whereas
extrathoracic metastases are uncommon.4,5 In the majority of
patients with thymoma, imaging is requested for investigation
of symptoms related to their tumors: either due to local
compression or invasion of thoracic structures or due to
systemic paraneoplastic disease. There is, however, an in-
creasing number of asymptomatic patients incidentally dis-
covered to have thymoma due to the increased utilization of
computed tomography (CT) for screening and the investiga-
tion of other symptoms of unrelated diseases. The goal of
imaging is to identify the tumor and stage it appropriately,
with emphasis on local invasion and distant spread because
invasion has been known as the most significant factor for
survival.6,7 The objectives of this review are to discuss the
imaging features of thymoma, the advantages, and limitations
of each imaging modality in establishing the diagnosis, stag-
ing, and prognosis of thymoma.
Initial investigation of a thymoma starts with a chest
radiograph, which is followed by chest CT for further char-
acterization and staging. Rarely, in selected cases, additional
imaging is used such as magnetic resonance imaging (MRI)
or nuclear medicine studies.
CHEST RADIOGRAPHY
Between 45 and 80% of thymomas are visible by chest
radiography.8 Thymomas usually appear as an ovoid or lob-
ulated, smooth, well-marginated mass, projecting over the
mediastinum typically protruding unilaterally (Figure 1), al-
though rarely may be seen to protrude bilaterally over the
mediastinum.8,9 The mass can be seen from the thoracic inlet
to the cardiophrenic angle. At times, the chest radiograph
may appear entirely normal and at other times changes may
be more subtle. The presence of a normal structure in the
anterior mediastinum, the anterior junction line, negates the
presence of an anterior mediastinal mass in the retrosternal
region. Unfortunately, the anterior junction line is seen in the
minority of normal individuals. This is a 1 to 3 mm line
created by four layers of pleura as the lungs approximate
anteriomedially, anterior to the heart and great vessels (Fig-
ure 2). Thickening of this line is a sign of a space-occupying
lesion in the anterior mediastinum (Figure 3). The lateral film
is of help for confirmation as often a mass will be seen in the
retrosternal region, and when small, may be more easily
detected on the lateral film without the superimposition of the
heart and mediastinum.
Chest radiographic signs for tumor invasiveness are
limited but should be searched for. These include an irregular
border with the adjacent lung, suggestive of invasion into the
lung; elevation of the hemidiaphragm, suggestive of phrenic
nerve involvement; and pleural nodularity.9
The advantage of the chest radiograph is in its low-
radiation dose, low price, and its availability. It lacks sensi-
tivity for smaller tumors and lacks specificity for differenti-
ating a thymoma from other anterior mediastinal masses,
such as metastatic disease, lymphoma, or for example, germ
cell tumor. Thus, once an anterior mediastinal mass is iden-
tified by chest radiography, patients should be further char-
acterized and staged by cross-sectional imaging, usually CT.
Patients with a normal chest radiograph but strong clinical
suspicion for thymoma are also referred for CT due to its
great sensitivity.
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COMPUTED TOMOGRAPHY
CT is more definite in the diagnosis of thymoma, with
its increased sensitivity in identifying mediastinal masses,
when compared with chest radiography. Thymomas have a
typical CT appearance that when seen is highly suggestive of
the diagnosis. In addition to the appearance of the primary
tumor, their pattern of spread differs from other tumors that
may be found in the anterior mediastinum. Thymoma rarely
presents with metastatic lymphadenopathy or with metastatic
pulmonary nodules where as other tumors, which com-
monly present with an anterior mediastinal mass, such as
lung cancer, do. Although intravenous contrast is not
needed for identification of the thymic mass, its role is
important with locally invasive tumors when evaluation of
the abutting vessels is crucial for preoperative staging
and therapeutic planning. Multiplannar reformatting of the
axial CT images is easily performed with the current use
of multidetector CT scanners and may aid in surgical
planning.
Typically, thymomas are closely related to the superior
pericardium that is anterior to the aorta, pulmonary artery, or
superior vena cava, although they have been described anywhere
from the lower neck to the cardiophrenic border (Figure 3). The
tumor is usually well defined, round or lobulated, homogenous,
and enhances after contrast injection.8 Nevertheless, at times, it
can be heterogeneous, or even cystic, because of areas of
hemorrhage and necrosis. The tumor can be partially or com-
pletely outlined by fat and may contain punctuate, course, or
FIGURE 1. Fifty-seven-year-old previously
healthy man imaged with a chest radiograph after
a motor vehicle accident. Posterior-anterior (A)
chest radiograph demonstrates a mass (curved
arrow) abutting and inseparable from the heart
confirmed to be in the anterior mediastinum
(black arrows) on the lateral chest radiograph (B).
Contrast-enhanced chest computed tomography
(CT) (C) revealed a 12 cm mass (T) compressing
the lateral wall of the right ventricle. Biopsy con-
firmed this to be a thymoma. H, heart.
FIGURE 2. Sixty-eight-year-old man imaged due
to symptoms of recurrent nausea and vomiting.
The frontal chest radiograph (A) shows a pencil
thin line (black arrowheads) from the level of the
right first costomanubrial junction proceeding ob-
liquely inferiorly to the left, which represents the
anterior junction line. Contrast-enhanced chest
computed tomography (CT) (B) shows this line
represents the point of contact of pleura as the
lungs come in contact anterior to the cardiovascu-
lar structures(white arrows).
Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010 Imaging Thymoma
Copyright © 2010 by the International Association for the Study of Lung Cancer S297
curvilinear calcifications8,9 (Figure 4). At presentation,
thymomas are usually 5 to 10 cm large although have been
described from a few millimeters to 34 cm.8
One of the important though challenging roles of CT is
to determine local tumor invasiveness. This is crucial as
tumor invasiveness has been shown to strongly correlate with
prognosis10,11 and dictates the therapeutic approach. The most
common staging system used today, which guides the CT
interpretation, is the Masaoka staging system.12 Briefly, stage
I is when the tumor is macroscopically and microscopically
completely encapsulated. Stage IIa is when there is macro-
scopic invasion into surrounding fatty tissue or mediastinal
pleura, whereas stage IIb is when there is microscopic inva-
sion into the capsule. Stage III is when there is macroscopic
invasion into a neighboring organ such as pericardium, great
vessels, or lung. Stage IVa is when there is pleural or
pericardial dissemination and stage IVb when there is lym-
phogenous or hematogenous metastatic disease. Stage IV is
readily identified by CT (Figure 4), and at times, local
invasion into neighboring organs can readily be seen such as
direct invasion into the superior vena cava, brachiocephalic
veins, heart, or encasement of coronary arteries (Figure 5). It
has been clinically known that CT cannot differentiate local
disease accurately, and indeed, involvement of the pericar-
dium (stage III) versus abutment of it and identification of
capsular or pericapsular involvement (stage II) cannot be
visualized directly. Unfortunately, there have been very few
studies looking at CT predictors of invasiveness, and those
that have been performed are small.
FIGURE 4. Contrast-enhanced chest computed tomogra-
phy (CT) of a 57-year-old woman obtained after an anterior
mediastinal mass was discovered on a routine chest radio-
graph. The CT shows an anterior mediastinal mass with cen-
tral calcifications and some heterogeneity with some low-
attenuation regions (curved arrow), whereas other shows
enhancement (medial to the calcifications). Note the pleural
drop metastasis (straight arrow). At surgery, patient was
found to have invasive thymoma with pleural drop metastases.
FIGURE 3. Sixty-one-year-old woman imaged for
staging of a newly discovered early breast cancer.
Posterior-anterior chest radiograph (A) shows
thickening of the anterior junction line (black ar-
rowheads) confirmed on the lateral chest radio-
graph (B) to represent an anterior mediastinal
mass (curved white arrow) anterior to but sepa-
rate from the ascending aorta (black arrowhead).
Contrast-enhanced chest computed tomography
(CT) (C) confirmed the presence of a well-demar-
cated lobulated anterior mediastinal mass
(straight white arrow) confirmed at surgery to
represent an invasive thymoma (stage II).
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There has been one study published so far, comparing
the CT appearance of 50 thymoma tumors to their Masaoka
staging.13 In this study, the authors attempted to separate
stage I disease from any capsular invasion. They found that
larger tumors were more likely to be invasive, although no
cutoff value was established. In their study, invasive tumors
were more likely to be heterogeneous with low-attenuation
areas within the tumor, which was seen in 60% of invasive
tumors (16/27), when compared with 22% (5/23) of stage I
tumors. Similarly, calcifications were more common in inva-
sive tumors, seen in 54% versus only 6% of stage I tumors.
Lobulated contours were more common in invasive tumors
(59%), when compared with stage I tumors (35%). Partial or
complete obliteration of fat planes around the tumor was not
helpful in distinguishing invasive (stages II–IV) from nonin-
vasive (stage I) thymomas. Most of the CT features showed
overlap, and a reliable distinction between stage I or higher
remains difficult.
There have been surgical series, trying to establish a
relationship between the size of thymoma and survival. Be-
cause size is readily available by CT, they should be men-
tioned. Smaller series looking at up to 70 patients with
thymoma found no correlation between tumor size and sur-
vival.14,15 On the other hand, larger surgical series looking at
118 to 179 patients found that larger tumors were associated
with worse outcome.6,16,17 There was no total agreement
between these studies on the cutoff value that would best
distinguish between the less favorable tumors as one sug-
gested 8 cm, another 10 cm, and the other 11 cm as the ideal
cutoff value. These cutoff values may be problematic, know-
ing that at CT most thymomas at presentation are 5 to 10 cm,
and thus fall within the uncertainty zone as to their prognosis.
Perhaps, the most important role of the initial CT is not
necessarily to distinguish stage I (purely encapsulated tumor)
from higher stages but to distinguish between those tumors
that should be treated with neoadjuvant therapy and those that
should proceed directly to surgery. Currently, it is recom-
mended that patients with stages III and IV should receive
neoadjuvant therapy.18–23 In an internal review of 57 surgi-
cally treated patients in M. D. Anderson Cancer Center, we
found that CT was able to distinguish early disease (stages I
and II) from more advanced disease (stages III and IV), data
that should be published shortly. Similar to the published
surgical series, we found that size was useful but only for the
extreme tumors. Tumors smaller than 5 cm were unlikely to
be invasive. Tumors larger than 11 cm were much more
likely to be advanced disease (stages III or IV). Nevertheless,
there was substantial overlap for those presenting with tumors
from 5 to 11 cm, and within this range, size could not reliably
distinguish between early and advanced disease.
There are few studies focusing on the CT appearance of
thymomas, when compared with the World Health Organi-
zation (WHO) classification. Unfortunately, in these studies,
thymic cancers were included in the evaluation.24–27 When
excluding the thymic cancers, CT could not distinguish be-
tween the different histologic subtypes of the WHO classifi-
cation for thymoma.24–27 This may be due to the inherent
problems within the WHO classification of thymoma, rather
than due to the imaging itself.11 Such problems include (a) the
poor interobserver and intraobserver reproducibility of the
pathology classifications; (b) the morphologic heterogeneity
and variations in morphology from field to field in thymoma;
and (c) the inability of the WHO classification system to
predict clinical outcome.7,28,29
CT is currently the cross-section modality of choice for
evaluating patients with a suspected anterior mediastinal
mass, and this is despite the relatively large radiation dose,
when compared with chest radiographs. CT is readily avail-
able and is quite accurate in distinguishing a mediastinal mass
caused by thymoma compared with other mediastinal tumors,
which usually differ in the appearance of the primary and the
pattern of metastatic spread, both of which are readily de-
tected by chest CT.
MAGNETIC RESONANCE IMAGING
The routine role of MRI in the identification and stag-
ing of thymoma is limited but is valuable in select circum-
stances. MRI features of thymoma are not specific. Thymoma
has signal characteristics similar to or higher than muscle on
T1-weighted images, and on T2-weighted images, the signal
is higher than muscle and may approach that of fat, making it
difficult to differentiate the thymoma from the surrounding
fat.8,30 Fat-suppression techniques may be useful in this
scenario (Figure 6). Heterogeneity of the tumor on MRI,
similar to what was seen in CT studies, is indeed associated
with more of an invasive status, but there is a great overlap,
and noninvasive tumors may also show this heterogeneity,
making this feature unreliable to distinguish invasive status
using this feature alone.26,31 In fact, such MRI features are
more useful for distinguishing thymic cancer rather than
FIGURE 5. Sixty-eight-year-old man evaluated due to weight
loss of 12 pounds during a period of a year, persistent hoarse-
ness, and chronic cough. Contrast-enhanced chest computed
tomography (CT) showed an infiltrative anterior mediastinal
mass biopsy proven to represent thymoma, contiguous with
the pericardium insinuating itself along the pericardial recesses
(black stars) surrounding the left main coronary artery (black
arrow). Note the compression of the superior vena cava (ar-
rowhead). a, ascending aorta.
Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010 Imaging Thymoma
Copyright © 2010 by the International Association for the Study of Lung Cancer S299
invasive status of thymoma.26 Dynamic MRI looking at time
to peak contrast enhancement, although used in other tumors,
cannot distinguish between thymoma and other major ante-
rior mediastinal masses such as thymic carcinoma, lym-
phoma, or germ cell tumor32 and, thus, is not used clinically.
Although MRI has the capabilities of multiplanar imaging,
this is easily obtained with multidetector chest CT with its
improved spatial resolution.
Under certain circumstances, MRI may prove valuable.
Patients, who cannot receive iodinated contrast material used
at CT, can have their vessels evaluated for possible invasion
by MRI. This can be performed with or without the use of
MRI contrast material (Figure 7). Because of MRIs superior
contrast resolution, when compared with CT, in select cases,
MRI can prove useful in identifying the nodular wall thick-
ening seen in cystic thymomas, absent from congenital
cysts.9,33 Rarely, thymic hyperplasia may be difficult to dis-
tinguish from diffuse thymoma. In cases where history is
most suspicious for thymoma and not for hyperplasia, chem-
ical shift MRI helps differentiate thymic hyperplasia from
thymic malignancy in patients 16 years of age or older.34,35
This technique relies on the difference in resonance fre-
quency between protons in water and those of protons in
trigyceride molecules. This technique is much more sensitive
in detecting microscopic fat within tissue as compared with
the detection of microscopic fat by fat-suppressed MR tech-
niques or with CT detection of fat. Finally, in patients in
whom detailed imaging of the lung is not of interest, and
radiation is to be avoided, MRI could prove a good substitute
to imaging instead of CT.
The advantage of MRI in investigating the anterior
mediastinum is the lack of radiation, the fact that vessel
involvement can be investigated without the use of intrave-
nous contrast and its superior contrast resolution. The disad-
vantage is that the examination is relatively lengthy and
provides poor investigation of the lung parenchyma. Thus, if
the etiology of the anterior mediastinal mass is not known,
complete investigation of it by MRI, including the lungs is
not optimal.
NUCLEAR MEDICINE
Although nuclear medicine techniques have been used
in the past for the evaluation of various thymic lesions, the
FIGURE 6. Sixty-two-year-old previously healthy man com-
plained of new cough and was found to have an anterior
mediastinal mass by chest radiography. Fat-suppressed T2-
weighted magnetic resonance imaging (MRI) axial image of
the chest at the level of the left pulmonary artery (*) shows
a heterogeneous high-intensity mass (M) involving the ante-
rior mediastinum displacing the mediastinum posteriorly. At
surgery, tumor was found to be invasive into perithymic fat,
stage IIa. a, aorta.
FIGURE 7. Fifty-three-year-old woman was found
to have mediastinal widening by chest radiography
after complaining of new facial swelling. A noncon-
trast enhanced magnetic resonance imaging (MRI)
was obtained for further characterization of the
mass and for evaluation of the superior vena cava.
Axial double inversion recovery sequence (A), a
black blood technique, at the level of the left pul-
monary artery (*), reveals an anterior mediastinal
mass (M) displacing the mediastinum posteriorly
(A  aorta), extending into the superior vena cava
(arrowhead). Axial Fiesta sequence (B) at the same
level of A shows the tumor within the superior vena
cava (arrowhead) using white blood technique.
Coronal imaging of the tumor within the superior
vena cava extending toward the right atrium (RA) is
demonstrated in both double inversion recovery,
black blood technique (C) and Fiesta sequence
(white blood technique) (D). Ao, ascending aorta;
LV, left ventricle.
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diagnostic criteria overlap considerably.36–38 Evaluation of
the thymus with thallium 201 (201Tl) is equal or superior to
that with CT. Using the early (15 minutes) and delayed
phases (180 minutes) after injection is helpful in differenti-
ating between the normal thymus, hyperplastic thymus, and
thymoma, in patients with myasthenia gravis.36 However, the
examination suffers from low resolution, low throughput, and
overlap in criteria.
Indium 111 octreotide shows increased uptake with
thymoma but does not differentiate hyperplasia from normal
thymus. Once again, its low spatial resolution limits its use
(Figure 8), but it has one advantage over morphologic imag-
ing. It is sometimes used to determine thymic tumor uptake to
identify patients who may respond to treatment with oct-
reotide, an octapeptide somatostatin analog that has a high
affinity for a selective somatostatin subtype (SST2) receptor.
In normal human thymus, the thymic epithelial cells seem to
be the major site of the SST production. Neuroendocrine
tumors show high affinity for octreotide and can be treated
with it. Octreotide alone or in combination with prednisone is
sometimes used as salvage therapy for patients with relapse
of advanced thymoma.39
During the last decade, positron emission tomography
(PET), in particular with [18F]fluorodeoxyglucose (FDG) has
proven useful for staging and imaging many tumors. Studies
assessing the evaluation of thymoma with FDG-PET are
small, but the data are not promising. Although FDG uptake
was found to be much higher in thymic cancer than thymoma,
the amount of uptake, or as it is termed standardized uptake
value (SUV), overlaps between the low-grade and high-grade
thymomas.40–43 Neither the FDG SUV nor another tracer
used with PET, carbon 11-labeled acetate can differentiate
between early thymoma, Masaoka stage I/II tumors, and stage
III/IV tumors. Thus, it cannot aid in trying to establish who
may benefit from neoadjuvant therapy. In addition, the FDG
activity of some thymomas can be similar to the mediastinal
blood activity and increased FDG uptake, similar to that seen
in thymomas that can be seen in patients with thymic hyper-
plasia. The latter is more common in the pediatric population,
found in 73% of untreated patients up to the age of 13 years
and in 8% of patients in their fourth decade.44 Patterns of
FDG activity and not just the SUV itself, in conjunction with
the CT appearance of the mediastinal abnormality, are helpful
in establishing the nature of disease. As with other malignan-
cies, FDG-PET was shown in a small thymoma study to be
particularly useful in the detection of distant malignant
spread41 (Figure 8). Whether this will prove to be cost
beneficial has not yet been shown.
FOLLOW-UP
There are no published recommendations as to the
frequency and timing of follow-up after treatment of thy-
moma nor is there consensus as to the imaging modality to be
used in this follow-up. Because late recurrence in thymoma is
not uncommon, seen even more than 5 or 10 years after
resection, follow-up may be lengthy. Because complete re-
section of recurrence obtains similar outcome compared with
those patients without recurrence, this follow-up may be
FIGURE 8. Sixty-seven-year-old woman with
stage IVa thymoma. Contrast-enhanced chest
computed tomography (CT) (A) shows an anterior
mediastinal mass (straight white arrow) with a
central calcification and pleural metastases
(curved arrows). Indium 111 octreotide coronal
whole body scan (B) demonstrates faint uptake in
the primary anterior mediastinal mass only
(straight black arrow). Normal uptake is seen in
the kidneys (K), liver (L), and spleen (curved black
arrow). Axial [18F]fluorodeoxyglucose positron
emission tomography (FDG-PET) scan (C) at the
level of CT image (B) demonstrates 18F-fluorode-
oxyglucose uptake in both the primary anterior
mediastinal tumor (black straight arrow) and the
pleural metastases (curved black arrow).
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justified.45–47 Currently, CT is most commonly used for this
follow-up. With the increased public concern of radiation in
young patients, it is unknown whether MRI will take a greater
role in this follow-up, despite its lower spatial resolution and
lengthy examination, when compared with CT. It also re-
mains to be seen whether FDG-PET will be used in this
follow-up or it will be reserved for selected cases such as
differentiating between nodular radiation changes and recur-
rence within the radiation field. If FDG uptake values will be
used to monitor disease progression/response, the FDG PET
scan must be performed in a meticulous matter, in the same
institution adhering to a strict imaging protocol, as SUV
measurements can be affected by many technical factors.
CONCLUSION
Imaging plays a crucial role in the diagnosis, staging,
and follow-up of patients with thymoma. The advantages and
disadvantages of each imaging modality were discussed.
Currently, CT is the cross-sectional modality of choice for
imaging thymoma. Whether MRI and/or PET-CT will play an
increasing role in this disease remains to be seen. Hopefully,
collaborative international studies48 will improve our under-
standing of this disease and enable us to predict local staging
by imaging to individualize patient care before surgery.
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